Biochemist Takes Charge of Beleaguered NIH Misconduct Office

NIH should take an active role in this process, , but I don’t think we should tell instituions what to do." The 46-year-old biochemist took up the challenge, on October 10. On that day she became the second NIH employee—and the first scientist direct NIH’s efforst on misconduct. The office she leads was created six years ago as part of effort to codify research practices by those who receive federal funds. But its work relating misconduct, which includes investigating allegati

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

NIH should take an active role in this process, , but I don’t think we should tell instituions what to do." The 46-year-old biochemist took up the challenge, on October 10. On that day she became the second NIH employee—and the first scientist direct NIH’s efforst on misconduct. The office she leads was created six years ago as part of effort to codify research practices by those who receive federal funds. But its work relating misconduct, which includes investigating allegations as well as developing prevention startegies, soon became a full-time job. And the pressures built as NIH’s handling of the subject become a matter of growing concern on Capitol Hill.

Newburgh is an eight-year veteran of NIH, having previously served as deputy director for pharmacological sciences at the general medical sciences institute. She was picked for the job because of her scientific background and her knowledge of NIH procedures, explains ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies